Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Cindy Donovan, PharmD

ViiV Healthcare

Disclosure(s): Johnson & Johnson: Stocks/Bonds; ViiV Healthcare: Employee/Salary, Stocks/Bonds

Poster(s):

1278 - Real World Treatment Experience of Single Tablet Dolutegravir/Lamivudine in Those Naïve to Treatment with Baseline Viral Loads ≥ 100,000 copies/mL in the US
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET
1279 - Real World Treatment Experience of Treatment-Naïve People with HIV who Initiated Treatment with Single Tablet Dolutegravir/Lamivudine in a Test and Treat setting in the US.
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET